Adimab has entered separate discovery collaborations with Biogen Idec and Novo Nordisk. Adimab will use its platform to identify fully human antibodies against two targets selected by Biogen and two from Novo Nordisk. Both Biogen and Novo Nordisk have the option to commercialize antibodies generated from the collaborations. Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales. Financ...